Hot Flashes Clinical Trials
Here are the 2 most popular medical studies for hot flashes
Anticholinergic Agent
Oxybutynin for Hot Flashes in Prostate Cancer
This trial compares the effect of oxybutynin (a medication) versus placebo for reducing hot flashes in men receiving androgen deprivation therapy (hormone therapy) for the treatment of prostate cancer.
Hormone Therapy
Estradiol for Hot Flashes
This study will evaluate whether there is a difference in the proportion of women who report a worsening severity of their hot flashes between three tapering schedules for one accepted HT/ET regimen. Secondarily, we hope to evaluate whether there is a difference in the frequency (number of occurrences per week), severity (defined as a subjective scale mild, moderate, or severe), and "Severity Index" (SI, equaling the product of both) of hot flashes between three tapering schedules for one accepted HT/ET regimen.
Popular filter options for hot flashes trials
Hot Flashes Clinical Trials With No Placebo
View 13 hot flashes medical studies that do not have a placebo group.
Behavioural Intervention
Vegan Diet + Soybeans for Hot Flashes
This trial tests if a vegan diet with soybeans can help reduce the frequency and severity of menopausal hot flashes, and if isoflavone intake is associated with the reduction in the frequency and severity of hot flashes.
Frequently Asked Questions
Introduction to hot flashes
What are the top hospitals conducting hot flashes research?
When it comes to finding relief from the discomfort of hot flashes, several hospitals are leading the way in clinical trials. In Palm Harbor, Florida, Suncoast Clinical Research takes the forefront with three ongoing trials dedicated to addressing hot flashes. Since their first recorded trial in 2011, they have been committed to finding effective solutions for this common symptom experienced by many women. Similarly, Helix Biomedics in Boynton Beach is making strides with two active trials and a recent entry into this area of research in 2021.
Meanwhile, New Port Richey's Suncoast Clinical Research Center joins the ranks with its own two ongoing hot flashes trials and an inaugural investigation also starting in 2021. Eastern Carolina Women's Center in New Bern has not only matched these numbers but also contributed since their first recorded trial back in 2011; showing commitment towards enhancing understanding through a further set of two active studies on hot flashes presently underway.
Lastly entering this space is Advances in Health located at Houston which marks its presence maintaining equivalent statistics as others:two currently running clinical tests accompanied by initiating their investigations recently duringthe year2021- demonstrating continuous growing interest towards resolving issues relatedto managing hot flushes
These hospitals signify hope for those experiencing disruptive hot flashes, providing opportunities for individuals to participate in cutting-edge research aimed at improving quality of life. By prioritizing these clinical trials and actively seeking innovative approaches, these institutions contribute significantly to advancing medical knowledge surrounding this uncomfortable symptom that affects countless people worldwide.
Which are the best cities for hot flashes clinical trials?
Raleigh, North carolina; Columbus, Ohio; Saginaw, Michigan; Memphis, Tennessee; and Mesa, Arizona are among the best cities for hot flashes clinical trials. These cities collectively offer a total of 6 active trials in Raleigh and Columbus, and 4 active trials in Saginaw, Memphis, and Mesa. The studies focus on various experimental treatments such as Elinzanetant (BAY3427080), MF101 5 g/day, EMBr Wave, Oxybutynin Chloride and others. Individuals experiencing hot flashes can potentially find opportunities to participate in cutting-edge research aimed at finding effective solutions to alleviate their symptoms within these cities.
Which are the top treatments for hot flashes being explored in clinical trials?
Hot flash research is actively exploring various treatments to alleviate this common menopausal symptom. One promising option is Elinzanetant (BAY3427080), which is currently being tested in three active trials dedicated to hot flashes. Since its first listing in 2018, it has already made an impact with ten clinical trials focused on this specific area. Another intriguing avenue being explored is a low-fat vegan diet supplemented with 1/2 cup of soybeans daily. While still in the early stages, one ongoing trial investigates the potential benefits of this dietary approach for managing hot flashes. As researchers delve deeper into these options, they bring us closer to finding effective relief for those experiencing disruptive hot flashes during menopause.
What are the most recent clinical trials for hot flashes?
Exciting developments are underway in the realm of hot flash treatment, with recent clinical trials shedding light on potential solutions. One such trial focuses on Elinzanetant (BAY3427080), a Phase 3 study that became available on 10/29/2021 and aims to address hot flashes. Another Phase 3 trial for Elinzanetant (BAY3427080) was conducted, becoming available on 8/27/2021. Additionally, Oxybutynin Chloride underwent a Phase 2 trial specifically targeting hot flashes and became available on 7/30/2021. These studies offer hope for those experiencing this often uncomfortable symptom by exploring novel treatments that may alleviate the impact of hot flashes.
What hot flashes clinical trials were recently completed?
Recently concluded clinical trials have made significant strides in improving the treatment of hot flashes, a common and often disruptive symptom. In July 2019, Astellas Pharma Global Development successfully completed a trial examining the efficacy of fezolinetant in alleviating hot flashes. Similarly, in April 2017, Dr. Alison Huang led a study investigating the use of transdermal nitroglycerin for managing this bothersome condition. These advancements offer hope for individuals experiencing hot flashes and highlight ongoing efforts to provide effective relief from this menopausal symptom.